Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue: 2012-2019

Historic Non-Current Deffered Revenue for Enanta Pharmaceuticals (ENTA) over the last 6 years, with Sep 2019 value amounting to $900,000.

  • Enanta Pharmaceuticals' Non-Current Deffered Revenue rose 51.77% to $900,000 in Q3 2019 from the same period last year, while for Sep 2019 it was $900,000, marking a year-over-year increase of 51.77%. This contributed to the annual value of $900,000 for FY2019, which is 51.77% up from last year.
  • According to the latest figures from Q3 2019, Enanta Pharmaceuticals' Non-Current Deffered Revenue is $900,000, which was down 2.49% from $923,000 recorded in Q2 2019.
  • In the past 5 years, Enanta Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $923,000 in Q2 2019 and a low of $161,000 during Q1 2015.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $676,000 (2017), whereas its average is $720,182.
  • In the last 5 years, Enanta Pharmaceuticals' Non-Current Deffered Revenue soared by 322.22% in 2015 and then fell by 14.06% in 2018.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Non-Current Deffered Revenue stood at $646,000 in 2015, then rose by 8.51% to $701,000 in 2016, then dropped by 6.70% to $654,000 in 2017, then climbed by 3.06% to $674,000 in 2018, then skyrocketed by 51.77% to $900,000 in 2019.
  • Its Non-Current Deffered Revenue stands at $900,000 for Q3 2019, versus $923,000 for Q2 2019 and $842,000 for Q1 2019.